ArticleBMC infectious diseases2026
Disease burden and outcomes of pediatric human bocavirus mono-infections: a three-year retrospective study from a large tertiary cohort.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman bocavirus 1 (HBoV1) is a respiratory virus predominantly affecting young children. Its independent pathogenic role has been increasingly recognized. This study aimed to evaluate the clinical course, risk factors, and outcomes of pediatric HBoV1 mono-infections over a three-year period.
methodsThis retrospective cohort included 1215 children (1 month–18 years) with HBoV1 mono-infection diagnosed by multiplex RT-PCR between 2021 and 2023 at a tertiary hospital. Patients were grouped based on chronic comorbidities: asthma, immunodeficiency, congenital heart disease, chronic respiratory disease, and none. Demographic, clinical, laboratory, and radiologic data were compared across groups. Logistic regression identified predictors of hospitalization and respiratory support.
resultsAmong 1215 cases, the median age was 3 years and 56.4% were male. A total of 414 patients (34.1%) were hospitalized, 99 (8.1%) required intensive care, and 33 (2.7%) were intubated. Overall, 23.2% had hypoxia at presentation. Chronic conditions were present in 309 patients (25.4%), and these children had significantly higher rates of severe outcomes. Respiratory support was required in 33.4% of the cohort. Multivariate analysis showed younger age (OR: 0.86), hypoxia (OR: 5.90), and abnormal chest imaging (OR: 26.2) as strong predictors of hospitalization (p < 0.001 for all). All 13 deaths (1.1%) occurred in patients with serious chronic illnesses, mostly immunodeficiencies and malignancies.
conclusionHBoV1 mono-infection can result in substantial morbidity, including hospitalization, respiratory failure, and death—particularly in children with chronic comorbidities. Key predictors such as age, hypoxia, and radiologic findings may help early risk stratification. Our findings reinforce the clinical significance of HBoV1 and highlight the need for vigilance in high-risk groups. CLINICAL
trial registrationThis study does not involve any clinical trials. Therefore, no clinical trial registration is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.